New York State Common Retirement Fund lessened its position in Cryolife Inc (NYSE:CRY) by 13.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 34,900 shares of the medical equipment provider’s stock after selling 5,300 shares during the period. New York State Common Retirement Fund owned about 0.09% of Cryolife worth $990,000 as of its most recent filing with the SEC.
Several other large investors have also recently modified their holdings of the company. Advisors Asset Management Inc. acquired a new stake in shares of Cryolife in the 4th quarter valued at $32,000. Synovus Financial Corp boosted its stake in shares of Cryolife by 25.0% in the 4th quarter. Synovus Financial Corp now owns 6,509 shares of the medical equipment provider’s stock valued at $185,000 after purchasing an additional 1,300 shares in the last quarter. LS Investment Advisors LLC boosted its stake in shares of Cryolife by 126.0% in the 4th quarter. LS Investment Advisors LLC now owns 2,581 shares of the medical equipment provider’s stock valued at $73,000 after purchasing an additional 1,439 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of Cryolife by 113.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,793 shares of the medical equipment provider’s stock valued at $79,000 after purchasing an additional 1,484 shares in the last quarter. Finally, Teachers Advisors LLC boosted its stake in shares of Cryolife by 3.5% in the 3rd quarter. Teachers Advisors LLC now owns 66,331 shares of the medical equipment provider’s stock valued at $2,335,000 after purchasing an additional 2,262 shares in the last quarter. Institutional investors own 71.34% of the company’s stock.
Several equities research analysts have recently commented on CRY shares. Zacks Investment Research downgraded shares of Cryolife from a “hold” rating to a “sell” rating in a research note on Wednesday, February 20th. Northland Securities reiterated a “buy” rating and set a $32.00 price target on shares of Cryolife in a research report on Thursday, January 17th. ValuEngine upgraded shares of Cryolife from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, January 2nd. Finally, Needham & Company LLC assumed coverage on shares of Cryolife in a research report on Wednesday, February 27th. They set a “hold” rating and a $29.65 target price on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $32.16.
Cryolife (NYSE:CRY) last posted its earnings results on Wednesday, February 13th. The medical equipment provider reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.07). Cryolife had a positive return on equity of 3.49% and a negative net margin of 1.45%. The business had revenue of $67.80 million for the quarter, compared to the consensus estimate of $67.10 million. As a group, research analysts anticipate that Cryolife Inc will post 0.31 earnings per share for the current year.
In other Cryolife news, VP Amy Horton sold 6,666 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $29.15, for a total transaction of $194,313.90. Following the completion of the transaction, the vice president now owns 103,713 shares of the company’s stock, valued at approximately $3,023,233.95. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Ronald D. Mccall sold 6,200 shares of the company’s stock in a transaction that occurred on Thursday, February 21st. The stock was sold at an average price of $29.26, for a total value of $181,412.00. Following the transaction, the director now directly owns 137,699 shares of the company’s stock, valued at approximately $4,029,072.74. The disclosure for this sale can be found here. Corporate insiders own 4.40% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Cryolife Inc (CRY) Holdings Cut by New York State Common Retirement Fund” was originally published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.baseballdailydigest.com/news/2019/04/21/cryolife-inc-cry-shares-sold-by-new-york-state-common-retirement-fund.html.
CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.
Featured Article: When is a capital gain realized?
Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.